412 related articles for article (PubMed ID: 28373470)
21. Mutated p53 in tumors, mutant p53 and p53-specific antibodies in the circulation in patients with gastric cancer.
Maeta M; Saito H; Oka S; Tsujitani S; Ikeguchi M; Kaibara N
J Exp Clin Cancer Res; 2000 Dec; 19(4):489-95. PubMed ID: 11277328
[TBL] [Abstract][Full Text] [Related]
22. Serum Anti-p53 Antibody Can Serve as a Predictive Marker for Histological Grade of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
Hata T; Mizuma M; Motoi F; Iseki M; Omori Y; Hayashi H; Nakagawa K; Morikawa T; Kamei T; Naitoh T; Furukawa T; Unno M
Pancreas; 2020 Jul; 49(6):768-773. PubMed ID: 32541631
[TBL] [Abstract][Full Text] [Related]
23. CA72-4 combined with CEA, CA125 and CAl9-9 improves the sensitivity for the early diagnosis of gastric cancer.
Yang AP; Liu J; Lei HY; Zhang QW; Zhao L; Yang GH
Clin Chim Acta; 2014 Nov; 437():183-6. PubMed ID: 25086284
[TBL] [Abstract][Full Text] [Related]
24. Value of Combined Detection of Serum CEA, CA72-4, CA19-9, CA15-3 and CA12-5 in the Diagnosis of Gastric Cancer.
Chen C; Chen Q; Zhao Q; Liu M; Guo J
Ann Clin Lab Sci; 2017 May; 47(3):260-263. PubMed ID: 28667025
[TBL] [Abstract][Full Text] [Related]
25. Low detection rate of p53 antibodies in sera of soft tissue sarcoma patients.
Würl P; Fittkau M; Meye A; Bartel F; Schmidt H; Schönfelder M; Taubert H
Cancer Lett; 2001 Sep; 170(2):199-205. PubMed ID: 11463499
[TBL] [Abstract][Full Text] [Related]
26. The Significance of Combined Measurement of p53 Antibody and other Tumor Markers for Colorectal Cancer after Curative Resection.
Kawahara D; Fujita F; Hayashi H; Matsuyama T; Eguchi S
Hepatogastroenterology; 2015 May; 62(139):624-8. PubMed ID: 26897942
[TBL] [Abstract][Full Text] [Related]
27. Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival.
Shiota G; Ishida M; Noguchi N; Oyama K; Takano Y; Okubo M; Katayama S; Tomie Y; Harada K; Hori K; Ashida K; Kishimoto Y; Hosoda A; Suou T; Kanbe T; Tanaka K; Nosaka K; Tanida O; Kojo H; Miura K; Ito H; Kaibara N; Kawasaki H
Dig Dis Sci; 2000 Jan; 45(1):122-8. PubMed ID: 10695624
[TBL] [Abstract][Full Text] [Related]
28. [Clinical value of serum CEA, CA19-9, CA72-4 and CA242 in the diagnosis and prognosis of gastric cancer].
Zhu YB; Ge SH; Zhang LH; Wang XH; Xing XF; DU H; Hu Y; Li YA; Jia YN; Lin Y; Fan B; Ji JF
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Feb; 15(2):161-4. PubMed ID: 22368025
[TBL] [Abstract][Full Text] [Related]
29. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
[TBL] [Abstract][Full Text] [Related]
30. CA19-9 is a significant prognostic marker of patients with stage III gastric cancer.
Kambara Y; Miyake H; Nagai H; Yoshioka Y; Shibata K; Asai S; Yuasa N
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1918-1924. PubMed ID: 32814681
[TBL] [Abstract][Full Text] [Related]
31. Combined detection of CEA, CA 19-9, CA 242 and CA 50 in the diagnosis and prognosis of resectable gastric cancer.
Tian SB; Yu JC; Kang WM; Ma ZQ; Ye X; Cao ZJ; Yan C
Asian Pac J Cancer Prev; 2014; 15(15):6295-300. PubMed ID: 25124614
[TBL] [Abstract][Full Text] [Related]
32. Carbohydrate antigen 19-9 is a useful prognostic marker in esophagogastric junction adenocarcinoma.
Tokunaga R; Imamura Y; Nakamura K; Uchihara T; Ishimoto T; Nakagawa S; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Oyama S; Shono T; Naoe H; Saeki H; Oki E; Watanabe M; Sasaki Y; Maehara Y; Baba H
Cancer Med; 2015 Nov; 4(11):1659-66. PubMed ID: 26310928
[TBL] [Abstract][Full Text] [Related]
33. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Sun Z; Zhang N
World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic and prognostic values of anti-helicobacter pylori antibody combined with serum CA724, CA19-9, and CEA for young patients with early gastric cancer.
Gong X; Zhang H
J Clin Lab Anal; 2020 Jul; 34(7):e23268. PubMed ID: 32118318
[TBL] [Abstract][Full Text] [Related]
35. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China.
Qiu LL; Hua PY; Ye LL; Wang YC; Qiu T; Bao HZ; Wang L
Cancer Detect Prev; 2007; 31(1):45-9. PubMed ID: 17292563
[TBL] [Abstract][Full Text] [Related]
36. The Changes and Clinical Significance of Preoperative and Postoperative Serum CEA and CA19-9 in Gastric Cancer.
Jing R; Cui M; Ju S; Pan S
Clin Lab; 2020 Apr; 66(4):. PubMed ID: 32255307
[TBL] [Abstract][Full Text] [Related]
37. Serum anti-p53 antibodies as a useful marker for prognosis of gastric carcinoma.
Mattioni M; Soddu S; Porrello A; D'Alessandro R; Spila A; Guadagni F
Int J Biol Markers; 2007; 22(4):302-6. PubMed ID: 18161662
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic significance of soluble human leukocyte antigen-G for gastric cancer.
Pan YQ; Ruan YY; Peng JB; Han QY; Zhang X; Lin A; Yan WH
Hum Immunol; 2016 Apr; 77(4):317-24. PubMed ID: 26788811
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of pretreatment serum carcinoembryonic antigen levels in gastric cancer with pathological lymph node-negative: A large sample single-center retrospective study.
Xiao J; Ye ZS; Wei SH; Zeng Y; Lin ZM; Wang Y; Teng WH; Chen LC
World J Gastroenterol; 2017 Dec; 23(48):8562-8569. PubMed ID: 29358864
[TBL] [Abstract][Full Text] [Related]
40. The use of tumor markers as predictors of prognosis in gastric cancer.
Mihmanli M; Dilege E; Demir U; Coskun H; Eroglu T; Uysalol MD
Hepatogastroenterology; 2004; 51(59):1544-7. PubMed ID: 15362797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
